Iradimed Corp ( (IRMD) ) has released its Q4 earnings. Here is a breakdown of the information Iradimed Corp presented to its investors.
IRADIMED CORPORATION is a prominent player in the development and supply of MRI-compatible medical devices, specializing in non-magnetic intravenous infusion pumps and patient vital signs monitoring systems for use during MRI procedures. Based in Winter Springs, Florida, the company is recognized for its innovative solutions that enhance patient safety during MRI scans.
In its latest earnings report, IRADIMED CORPORATION announced record-breaking revenues of $19.4 million for the fourth quarter of 2024, marking an 11% increase from the previous year. The company also reported a full-year revenue increase of 12% year-on-year. Alongside these financial achievements, the company declared an increase in its quarterly cash dividend to $0.17 per share, reflecting its commitment to returning value to shareholders.
Key financial highlights include a GAAP diluted EPS of $0.40 and a non-GAAP diluted EPS of $0.44 for Q4 2024, with full-year GAAP and non-GAAP EPS reported at $1.50 and $1.66, respectively. The company’s robust financial performance was driven by strong demand for its MRI-compatible IV infusion pump systems, which saw significant sales growth. Additionally, the construction of a new facility in Orlando is progressing well, expected to be completed mid-year 2025, which will support future growth.
Looking ahead, IRADIMED CORPORATION anticipates continued financial growth, with projected revenues for 2025 ranging from $78 million to $82 million and GAAP diluted EPS expected between $1.55 and $1.65. The company remains focused on delivering innovative solutions in the MRI-compatible medical device market and driving long-term value for its customers and shareholders.